MIAMI, May 1, 2026
InspireMD, Inc. announced a voluntary U.S. recall of its CGuard® Prime 135 cm carotid stent delivery system, following performance concerns identified during a controlled product launch. The decision, taken in consultation with the U.S. Food and Drug Administration (FDA), reflects the company’s proactive approach to ensuring device quality and procedural reliability, while maintaining confidence in its core stent technology used for stroke prevention.
Recall Driven by Performance, Not Patient Safety
The recall specifically targets the CGuard Prime 135 cm delivery system, where technical success rates in carotid artery stenting (CAS) procedures did not meet internal performance expectations. Importantly, InspireMD emphasized that this action has no safety implications for patients already treated, and the underlying CGuard stent implant continues to demonstrate strong clinical outcomes, including low adverse event rates and durable stroke prevention. This distinction is critical, as it separates delivery system limitations from the therapeutic effectiveness of the implant itself.
Product Pipeline and Regulatory Roadmap Remain Active
Despite the recall, InspireMD’s broader product strategy remains intact. The company continues to anticipate FDA approval of its original CGuard delivery system in Q3 2026, which has already been used in over 70,000 procedures globally. Additionally, development of the CGuard Prime 80 cm delivery system for transcarotid artery revascularization (TCAR) is progressing, with approval expected in the second half of 2026. The company is also advancing its SwitchGuard neuroprotection system, targeting potential regulatory clearance by 2027. These efforts signal continued momentum in expanding minimally invasive stroke prevention technologies.
Advertisement
Commercial Impact and Strategic Adjustment
The recall has immediate business implications, with InspireMD withdrawing its full-year 2026 revenue guidance due to the temporary pause in U.S. commercialization. However, the company reported strong global demand, including 53% year-over-year unit sales growth and 34% quarter-over-quarter growth in the U.S., highlighting sustained market interest in its carotid stent platform. The recall is positioned as a strategic quality-driven decision, prioritizing long-term product performance and physician confidence over short-term revenue continuity.
Technology Focus: Advancing Carotid Intervention
InspireMD’s platform is built on its proprietary MicroNet™ mesh technology, designed to enhance embolic protection and improve outcomes in carotid interventions. With approximately 35,000 TCAR procedures performed annually in the United States, expansion into this segment could significantly increase the company’s addressable market. The ongoing refinement of delivery systems and integration with neuroprotection technologies underscores a broader industry shift toward precision-guided, minimally invasive vascular treatments.
Source: InspireMD press release
